Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rxo (RXO) Operating Expenses (2021 - 2025)

Rxo's Operating Expenses history spans 5 years, with the latest figure at $200.0 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 8.26% year-over-year to $200.0 million; the TTM value through Dec 2025 reached $832.0 million, up 24.92%, while the annual FY2025 figure was $832.0 million, 24.92% up from the prior year.
  • Operating Expenses reached $200.0 million in Q4 2025 per RXO's latest filing, down from $208.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $218.0 million in Q4 2024 to a low of $130.0 million in Q3 2021.
  • Average Operating Expenses over 5 years is $167.3 million, with a median of $154.5 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: dropped 13.25% in 2023, then surged 49.32% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $152.0 million in 2021, then grew by 1.97% to $155.0 million in 2022, then decreased by 5.81% to $146.0 million in 2023, then soared by 49.32% to $218.0 million in 2024, then fell by 8.26% to $200.0 million in 2025.
  • Per Business Quant, the three most recent readings for RXO's Operating Expenses are $200.0 million (Q4 2025), $208.0 million (Q3 2025), and $214.0 million (Q2 2025).